Retatrutide

Description

Retatrutide (LY3437943) For Sale — 12mg Research Vial

Retatrutide (LY3437943) is a novel triple-hormone receptor agonist currently in Phase 3 clinical trials. Unlike dual agonists, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors — a mechanism that researchers believe accounts for its substantially greater metabolic effects compared to previous-generation GLP-1 compounds.

Research Profile

In published Phase 2 data (NEJM, 2023), retatrutide demonstrated an average 24.2% reduction in body weight over 48 weeks — exceeding tirzepatide (~20.9%) and semaglutide (~14.9%) in comparable studies. The glucagon receptor component adds a thermogenic dimension not present in dual agonists. Researchers studying obesity pathways, metabolic syndrome, and energy expenditure have cited retatrutide as the most mechanistically comprehensive compound in its class to date.

Product Specifications

• Compound: Retatrutide (LY3437943)
• Amount: 12mg per vial
• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Testing: Third-party Certificate of Analysis available on request
• Storage: Store lyophilized at -20°C; reconstituted at 4°C, use within 28 days
• For laboratory and research use only — not for human consumption

For research and laboratory use only. Not intended for human consumption. Retatrutide is not FDA-approved for any indication.